Product
AUR105
1 clinical trial
4 indications
Indication
Solid TumorIndication
AdultIndication
Non-Hodgkin LymphomaIndication
Hodgkin lymphomaClinical trial
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR105 in Patients With Relapsed Advanced Malignancies (SURYA-1)Status: Recruiting, Estimated PCD: 2025-12-30